Drugs / ICVAX
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06253533 | Feb 2023 → Sep 2024 | HIV infectious disease | Immuno Cure Holding (HK) Limited | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ICVAX | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06253533 ↗ |
| Route | Intramuscular | “ICVAX and Placebo will be administered via intramuscular injection followed by electroporation” NCT06253533 ↗ |